RAPT Therapeutics, Inc.
NASDAQ:RAPT
Overview | Financials
Company Name | RAPT Therapeutics, Inc. |
Symbol | RAPT |
Currency | USD |
Price | 0.825 |
Market Cap | 28,854,581 |
Dividend Yield | 0% |
52-week-range | 0.789 - 27.35 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Brian Russell Wong M.D., Ph.D. |
Website | https://www.rapt.com |
An error occurred while fetching data.
About RAPT Therapeutics, Inc.
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD